Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus penpulimab as neoadjuvant therapy for locally advanced head and neck squamous cell carcinoma
ChiCTR2200059634Phase 2Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- May 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and penpulimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Objective response rate. Planned start May 2022; status: not yet recruiting.
02
Drugs
anlotinibpenpulimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2200059634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059634.